INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 30 April 2016
|
Net Assets |
£188m |
|
Net Assets per share |
489p |
|
Share price |
430p |
|
Total value of unquoted investments |
£20m |
|
Total number of portfolio companies |
86 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Amgen |
8.2 |
|
Celgene |
6.6 |
|
Gilead |
6.1 |
|
Biogen |
5.9 |
|
Medivation |
5.0 |
|
Genmab |
3.7 |
|
Ophthotech |
3.2 |
|
Alexion |
3.2 |
|
Incyte |
2.9 |
|
Biomarin |
2.6 |
|
|
----------- |
|
Total |
47.4 |
|
Portfolio Revenue Split |
% NAV |
|
Revenue Generating |
71 |
|
Near Revenue |
4 |
|
No sales in the near term |
25 |
|
|
----------- |
|
Total |
100 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
81 |
|
Europe & UK |
19 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
89 |
|
Unquoted |
11 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
24 MAY 2016